Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
Postpartum Preeclampsia, Hypertension in Pregnancy
About this trial
This is an interventional treatment trial for Postpartum Preeclampsia focused on measuring Nifedipine, Labetalol, Postpartum, Hypertension, Preeclampsia, Pregnancy
Eligibility Criteria
Inclusion Criteria:
Any patient admitted for delivery by cesarean or vaginal delivery at 24 weeks gestation or greater with hypertension(HTN). Hypertension will be defined during the study as either a systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg on two occasions at least 4 hours apart. This definition is consistent with the ACOG definition for pregnancy related HTN. Following enrollment, treatment will be escalated at discretion of primary provider with the goal of normotension.
Exclusion Criteria:
History of moderate persistent asthma, coronary artery disease, heart failure, AV heart block, pulmonary edema
- Contraindication to either Nifedipine or Labetalol
- HR <60 or >110
- Native language other than English or Spanish
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Nifedipine
Labetalol
Patients randomized to Nifedipine will be started on Nifedipine XR 30mg BID. Escalation in therapy to be determined by primary provider. Maximum dose of Nifedipine is 120mg daily. All patients will be monitored for signs and symptoms of hypotension or medication side effect- severe HA, orthostasis, syncope.
Patients randomized to Labetalol will be started on 200mg TID. Escalation in therapy to be determined by primary provider. Maximum dose is 2400mg in a day. All patients will be monitored for signs and symptoms of hypotension or medication side effect- orthostasis, syncope, bradycardia.